|
|||
| |
|||
The company's initial product focus is vaccines and therapeutics against seasonal and pandemic influenza. The company are developing a novel nanobiomolecular platform, which is comprised of a biocompatible, synthetic and scalable delivery system for vaccines and therapeutics against infectious diseases and cancer. The product can be utilized to deliver different types of bioactive molecules including peptides and gene based vaccines.
Access the contact details for this post by subscribing to premium content membership. For more details on premium content membership see our membership and fees page >> or contact info@nanoposts.com, Tel: +44(0)1786 474768. |
||
| CLICK HERE If you would like to receive contact details for this technology provider or ask a question (s) |
 |
|
Privacy Statement | Terms of Use
T: +44 (0) 1786 474768 E: info@nanoposts.com |
|||||